Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 4, 2011, Pages 503-506

  Katsios, Christos ^a   Baltogiannis, George ^a   Roukos, Dimitrios H ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

chemotherapy; epigenetics; gastric cancer; miRNAs; radiotherapy; surgery; targeted therapy

Indexed keywords

CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRASTUZUMAB; WNT PROTEIN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DNA MODIFICATION; DRUG TARGETING; EPIGENETICS; GASTRECTOMY; HUMAN; LYMPHADENECTOMY; ONCOGENE NEU; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; EPIGENESIS, GENETIC; GENOME; HUMANS; META-ANALYSIS AS TOPIC; MICRORNAS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 79955124541     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.15     Document Type: Review

References (24)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
2. Jemal A, Siegel R, Xu JQ, Ward E. Cancer Statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006). (Pubitemid 46655601)
4. Wu CW, Hsiung CA, Lo SS et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 7(4), 309-315 (2006).
5. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 11(5), 439-449 (2010).
6. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303(17), 1729-1737 (2010).
7. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357(18), 1810-1820 (2007). (Pubitemid 350044801)
8. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
9. Schuhmacher C, Gretschel S, Lordick F et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J. Clin. Oncol. 28(35), 5210-5218 (2010).
10. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 28(9), 1547-1553 (2010).
11. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
12. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
13. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010).
14. Petrelli NJ, Winer EP, Brahmer J et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 27(35), 6052-6069 (2009).
15. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760-774 (2010).
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
17. Heard E, Tishkoff S, Todd JA et al. Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet. 11(10), 723-733 (2010).
18. Lander ES. Initial impact of the sequencing of the human genome. Nature 470(7333), 187-197 (2011).
19. Roy S, Ernst J, Kharchenko PV et al. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science 330(6012), 1787-1797 (2010).
20. Tamsir A, Tabor JJ, Voigt CA. Robust multicellular computing using genetically encoded NOR gates and chemical 'wires'. Nature 469(7329), 212-215 (2010).
21. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010).
22. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28(10), 1069-1078 (2010).
23. Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol. 7(12), 668-680 (2010).
24. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 467(7315), 543-549 (2010).